Nyxoah Raises €15 Million in New Financing, Completes BLAST OSA Clinical Study Read more about Nyxoah Raises €15 Million in New Financing, Completes BLAST OSA Clinical Study
Nyxoah Receives European CE Mark Approval for the Genio® System, a Disruptive Neurostimulation Solution for Obstructive Sleep Apnea Therapy Read more about Nyxoah Receives European CE Mark Approval for the Genio® System, a Disruptive Neurostimulation Solution for Obstructive Sleep Apnea Therapy
Nyxoah publishes positive Obstructive Sleep Apnea data from BLAST OSA study in the European Respiratory Journal Read more about Nyxoah publishes positive Obstructive Sleep Apnea data from BLAST OSA study in the European Respiratory Journal
Benefits and safety of Genio® system implantation technique published in Laryngoscope Investigative Otolaryngology Read more about Benefits and safety of Genio® system implantation technique published in Laryngoscope Investigative Otolaryngology
Nyxoah announces appointment of new CEO Olivier Taelman Read more about Nyxoah announces appointment of new CEO Olivier Taelman
Nyxoah raises €25 million in private funding round Read more about Nyxoah raises €25 million in private funding round
Successful first implantation of two patients in Benelux with the Genio® system Read more about Successful first implantation of two patients in Benelux with the Genio® system
Nyxoah Announces Intention to Launch an Initial Public Offering on Euronext Brussels Read more about Nyxoah Announces Intention to Launch an Initial Public Offering on Euronext Brussels
Nyxoah launches its Initial Public Offering on Euronext Brussels Read more about Nyxoah launches its Initial Public Offering on Euronext Brussels
Nyxoah receives IDE approval from the U.S. Food and Drug Administration (FDA) for its DREAM study Read more about Nyxoah receives IDE approval from the U.S. Food and Drug Administration (FDA) for its DREAM study